Copyright © 2019 by Astraea Therapeutics LLC. All rights reserved.

PUBLICATIONS

NOP-Targeted Nonpeptide Ligands

Zaveri NT, Meyer ME

Handbook of Experimental Pharmacology. 2019 May 22

Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists

Mann A, Moulédous L, Froment C, O'Neill PR, Dasgupta P, Günther T, Brunori G, Kieffer BL, Toll L, Bruchas MR, Zaveri NT, Schulz S.

Science Signaling. 2019 March 26

The nociceptin receptor (NOP) agonist AT-312 blocks acquisition of morphine- and cocaine-induced conditioned place preference in mice

Zaveri NT, Marquez PV, Meyer ME, Hamid A, Lufty K

Frontiers in Psychiatry. 2018 November 29

 

Neuronal nicotinic acetylcholine receptors mediate ∆9 -THC dependence: Mouse and human studies

Donvito G, Muldoon PP, Jackson KJ, Ahmad U, Zaveri NT, McIntosh JM, Chen X, Lichtman AH, Damaj MI

Addiction Biology. 2018 October 31

A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid effects in nonhuman primates

Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, Czoty PW, Kishioka S, Zaveri NT, Ko MC

Science Translational Medicine. 2018 August 29

Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists

Arcuri L, Novello S, Frassineti M, Mercatelli D, Pisanò CA, Morella I, Fasano S, Journigan BV, Meyer ME, Polgar WE, Brambilla R, Zaveri NT, Morari M

British Journal of Pharmacology. 2018 March

A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl) piperidin-4-yl) -1H-indol-2-yl) methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice

Zaveri NT, Marquez PV, Meyer ME, Polgar WE, Hamid A, Lutfy K.

Alcoholism: Clinical and Experimental Research. 2018 February

Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs

Cippitelli A, Brunori G, Schoch J, Armishaw CJ, Wu J, Zaveri NT, Giulianotti MA, Welmaker GS, Toll L

Psychopharmacology (Berl). 2018 June

Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships

Journigan VB, Polgar WE, Tuan EW, Lu J, Daga PR, Zaveri NT

Scientific Reports. 2017 October 16

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403

Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, Lambert DG, Calo' G, Zaveri NT

Pharmacology Research and Perspectives. 2017 August

Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation

Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo' G, Rampon C, Frances B, Mouledous L

Neuropharmacology. 2017 October

The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats

Yuan M, Malagon AM, Yasuda D, Belluzzi JD, Leslie FM, Zaveri NT

Behavioural Brain Research. 2017 August 30

Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption

Kallupi M, Shen Q, de Guglielmo G, Yasuda D, Journigan VB, Zaveri NT, Ciccocioppo R

Addiction Biology. 2018 March

In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations

Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV, Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C, Zaveri NT, Calo G

European Journal of Pharmacology. 2016 December 15

A key role for the N/OFQ-NOP receptor system in modulating nicotine taking in a model of nicotine and alcohol co-administration

Cippitelli A, Schoch J, Debevec G, Brunori G, Zaveri NT, Toll L

Scientific Reports. 2016 May 20

Nociceptin/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT

Pharmacological Reviews. 2016 April

Nociceptin opioid receptor (NOP) as a therapeutic target: progress in translation from preclinical research to clinical utility

Zaveri NT

Journal of Medicinal Chemistry. 2016 August 11

Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands

Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, Gavioli EC, Calo' G

Neuropharmacology. 2016 June